Transcatheter structural heart therapies stand to replace their open-heart counterparts thanks to technological innovations and expanded patient access.
Improved functionality across four valve sizes and lowest delivery profile on market, Evolut PRO+ TAVR System launches in U.S. as TAVR patient population grows.